Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis

BACKGROUND: High-grade glioma (HGG) is a fatal human cancer. Bortezomib, a proteasome inhibitor, has been approved for the treatment of multiple myeloma but its use in glioma awaits further investigation. This study aimed to explore the chemotherapeutic effect and the underlying mechanism of bortezo...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Jun-Hai, Yang, Lin, Chen, Ju-Xiang, Li, Qing-Rui, Zhu, Li-Rong, Xu, Qing-Fu, Huang, Guo-Hao, Zhang, Zuo-Xin, Xiang, Yan, Du, Lei, Zhou, Zheng, Lv, Sheng-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892143/
https://www.ncbi.nlm.nih.gov/pubmed/31796105
http://dx.doi.org/10.1186/s40880-019-0424-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892143/
https://www.ncbi.nlm.nih.gov/pubmed/31796105
http://dx.doi.org/10.1186/s40880-019-0424-2

Ejemplares similares